SAN FRANCISCO, Calif., August 5, 2013 — CollabRx, Inc. (CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, was featured a Forbes article “Can We Build A Kickstarter For Cancer?,” written by Paul Howard.
An excerpt from the article stated:
Web-based tools and apps (e.g., from CollabRx.com) that can mine expert-curated molecular models of specific cancers (like melanoma) can guide treatment decisions (and feed those outcomes, good and bad, back into the research process). Cancer patients would benefit from research focused on their individual diseases – in real time. The resulting knowledge gained would improve cancer outcomes for all cancer patients and help de-risk cancer drug-development programs. Cancer drug development time frames could be slashed from one to two decades to two to five years fast enough to make a difference in the lives of tens of thousands of patients..
In 2013, 1.6 million Americans will be diagnosed with cancer, with 580,000 succumbing to it. Only 48,000 cancer patients will enter clinical trials. The remaining 1.55 million will receive the “standard of care” – and while this may be curative for patients with early stage or highly responsive cancers, for far too many patients, it will buy them little time at the cost of serious side effects. Indeed, it is these patients who would most benefit from participating in a movement focused on distributed research and learning.
To view the article in its entirety please visit the following link: http://www.forbes.com/sites/theapothecary/2013/08/01/can-we-build-a-kickstarter-for-cancer/
CollabRx began its commercialization effort of web-based tools and apps to inform clinical decision making in molecular medicine, in the Company’s fourth quarter ended March 31, 2013. Working with leading partners in the space, CollabRx believes it is positioned as virtually the only pure-play public company in the sector.
CollabRx, Inc. (CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contacts:
Thomas R. Mika, CEO
James Carbonara, Regional Vice President